Apellis Pharmaceuticals Inc
APLS
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
198.6% downsideOvervalued by 198.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.25 Billion |
|---|---|
| Enterprise Value | $4.96 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.18 |
| Beta | -0.25 |
| Outstanding Shares | 126,024,000 |
Return
| Return on Equity | 32.12% |
|---|---|
| Return on Assets | 12.31% |
| Return on Invested Capital | 20.21% |
Valuation & Multiples
| P/E Ratio | 38.71 |
|---|---|
| PEG | -32.19 |
| Price to Sales | 8.21 |
| Price to Book Ratio | 13.68 |
| Enterprise Value to Revenue | 6.69 |
| Enterprise Value to EBIT | 30.72 |
| Enterprise Value to Net Income | 37 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.27 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.7182▲ 46.05% |
|---|---|
| Total Calls | 949,600▼ 74.19% |
| Total Puts | 682,032▼ 28.07% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 110.84%▲ 10.54% |
|---|---|
| Total Invested | $5.55B▲ 74.90% |
| Investors Holding | 341▲ 32.00% |
ESG Score
No data
About Apellis Pharmaceuticals Inc
CEO: Cedric Francois Relevant Senate Committees
Most critical committee for revenue. Oversees Medicare and Medicaid, dictating drug reimbursement rates and the implementation of the Inflation Reduction Act's drug pricing provisions.
Directly oversees the FDA and NIH; members have early access to information regarding drug approval standards and clinical trial regulations.
Directly oversees intellectual property and patent law, which are critical for protecting the exclusivity of Apellis's C3 targeted therapies.
APLS's lead product Syfovre treats geographic atrophy, an age-related condition. This committee's focus on drug pricing and senior health creates high headline and regulatory risk.